Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The cardiovascular effects of ertugliflozin, an inhibitor of sodium-glucose cotransporter 2, have not been established. METHODS: In a multicenter, double-blind trial, we randomly assigned patients with type 2 diabetes and atherosclerotic cardiovascular disease to receive 5 mg or 15 mg of ertugliflozin or placebo once daily. With the data from the two ertugliflozin dose groups pooled for analysis, the primary objective was to show the noninferiority of ertugliflozin to placebo with respect to the primary outcome, major adverse cardiovascular events (a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke). The noninferiority margin was 1.3 (upper boundary of a 95.6% confidence interval for the hazard ratio [ertugliflozin vs. placebo] for major adverse cardiovascular events). The first key secondary outcome was a composite of death from cardiovascular causes or hospitalization for heart failure. RESULTS: A total of 8246 patients underwent randomization and were followed for a mean of 3.5 years. Among 8238 patients who received at least one dose of ertugliflozin or placebo, a major adverse cardiovascular event occurred in 653 of 5493 patients (11.9%) in the ertugliflozin group and in 327 of 2745 patients (11.9%) in the placebo group (hazard ratio, 0.97; 95.6% confidence interval [CI], 0.85 to 1.11; P<0.001 for noninferiority). Death from cardiovascular causes or hospitalization for heart failure occurred in 444 of 5499 patients (8.1%) in the ertugliflozin group and in 250 of 2747 patients (9.1%) in the placebo group (hazard ratio, 0.88; 95.8% CI, 0.75 to 1.03; P = 0.11 for superiority). The hazard ratio for death from cardiovascular causes was 0.92 (95.8% CI, 0.77 to 1.11), and the hazard ratio for death from renal causes, renal replacement therapy, or doubling of the serum creatinine level was 0.81 (95.8% CI, 0.63 to 1.04). Amputations were performed in 54 patients (2.0%) who received the 5-mg dose of ertugliflozin and in 57 patients (2.1%) who received the 15-mg dose, as compared with 45 patients (1.6%) who received placebo. CONCLUSIONS: Among patients with type 2 diabetes and atherosclerotic cardiovascular disease, ertugliflozin was noninferior to placebo with respect to major adverse cardiovascular events. (Funded by Merck Sharp & Dohme and Pfizer; VERTIS CV ClinicalTrials.gov number, NCT01986881.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The trial of once-weekly exenatide demonstrated a directionally favorable effect on MACE but narrowly missed statistical significance.644”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [644]
In the citing paper
“In the CVOTs Harmony Outcomes (albiglutide vs placebo), EXSCEL (exenatide LA vs placebo), and AMPLITUDE-O (efpeglenatide vs placebo), there were numerically fewer strokes, but HRs were not significant.472,641,644”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [644]
In the citing paper
“The SGLT2i cardiovascular outcome trials (CVOTs) have reported DKA rates of 0.1 -0.6% compared with rates of < 0.1 -0.3% with placebo (143 -147), with very low rates in the HF (148 -151) and CKD (152,153) outcome studies.”
In the citing paper
“In the Evaluation of Ertugli fl ozin Ef fi cacy and Safety CVOT (VERTIS CV), which recruited exclusively people with established CVD and type 2 diabetes, ertugli fl ozin was similar to placebo with respect to the primary MACE outcome and all key secondary outcomes (including a composite kidney outcome) except for HHF (146).”
In the citing paper
“While there was a trend for bene fi t for the key secondary endpoint of cardiovascular death or heart failure hospitalization, this did not meet statistical signi fi cance (HR: 0.88; 95% CI: 0.75 -1.03).”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [91]
18 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382
Self-citationCanagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189
Self-citationEmpagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Wanner, C., Inzucchi, S. E., Lachin, J. M., Fitchett, D., von Eynatten, M., Mattheus, M., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Zinman, B. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1515920 · Cited by 3,655
Mortality and cardiovascular disease in type 1 and type 2 diabetes
Rawshani, A., Rawshani, A., Franzén, S., Eliasson, B., Svensson, A.-M., Miftaraj, M., McGuire, D. K., Sattar, N., Rosengren, A., & Gudbjörnsdottir, S. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1608664 · Cited by 1,389
Self-citationKDOQI clinical practice guideline for diabetes and CKD: 2012 update
(2012) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2012.07.005 · Cited by 1,320
Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease
Thomas, M. C., Cooper, M. E., & Zimmet, P. (2016) · Nature Reviews Nephrology · doi:10.1038/nrneph.2015.173 · Cited by 742
Interim analysis: The alpha spending function approach
Demets, D. L., & Lan, K. K. G. (1994) · Statistics in Medicine · doi:10.1002/sim.4780131308 · Cited by 564
Cannon, C. P., McGuire, D. K., Pratley, R., Dagogo-Jack, S., Mancuso, J., Huyck, S., Charbonnel, B., Shih, W. J., Gallo, S., Masiukiewicz, U., et al. (2018) · American Heart Journal · doi:10.1016/j.ahj.2018.08.016 · Cited by 203
Self-citation
Research works printed but not linked: 1
- Food and Drug Administration. Guidance for industry: diabetes mellitus — evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. Fed Regist 2008;73(245):77724-77725 (https://www.govinfo.gov/content/pkg/FR-2008-12-19/pdf/E8-30086.pdf).
Cited by
Items 501–600 of 1,001
Ferrannini, E., Baldi, S., Scozzaro, T., Tsimihodimos, V., Tesfaye, F., Shaw, W. C., Rosenthal, N. R., Figtree, G. A., Neal, B. C., Mahaffey, K. W., et al. (2022) · Diabetes Care · doi:10.2337/dc21-2398 · Cited by 20
Teo, Y. H., Chia, A. Z. Q., Teo, Y. N., Chong, E. Y., Syn, N. L. X., Cheong, J. Y. A., Ong, H. T., Wee, C. F., Ting, A. Z. H., Tan, J. T. A., et al. (2022) · Journal of Hypertension · doi:10.1097/hjh.0000000000003280 · Cited by 18
“Furthermore, several large randomized controlled trials have been published in 2020 [24,25] which will provide further evidence for the BP reduction effects in SGLT inhibitors.”
BackgroundPistelli, L., Parisi, F., Correale, M., Cocuzza, F., Campanella, F., Ferrari, T. D., Crea, P., Sarro, R. D., Cognata, O. M. L., Ceratti, S., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12010379 · Cited by 22
“Differently, another SGLT-2i, ertuglifozin, was inexplicably not superior to placebo in improving cardiovascular outcomes among a population that was similar to those analyzed in trials involving empaglifozin, dapaglifozin and sotaglifozin [75].”
ResultA review of the evidence on cardiovascular outcomes from obesity treatment
Wahab, R. A., & le Roux, C. W. (2023) · Obesity Pillars · doi:10.1016/j.obpill.2023.100071 · Cited by 21
Shokravi, A., Seth, J., Lu, N., & Mancini, G. B. J. (2025) · Cardiovascular Diabetology – Endocrinology Reports · doi:10.1186/s40842-025-00248-2 · Cited by 17
The effects of antidiabetic agents on heart failure
Wijnen, M., Duschek, E. J. J., Boom, H., & van Vliet, M. (2021) · Netherlands Heart Journal · doi:10.1007/s12471-021-01579-2 · Cited by 17
Rasalam, R. R., Atherton, J. J., Deed, G., Molloy‐Bland, M., Cohen, N. D., & Sindone, A. P. (2021) · ESC Heart Failure · doi:10.1002/ehf2.13483 · Cited by 19
“Nevertheless, confidence intervals for this result still overlap with other studies.(7) Also, despite not meeting its primary endpoint, a 30% reduction in the risk of HHF was observed.”
MethodResultLam-Chung, C. E. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1174692 · Cited by 20
Diabetes among Muslims during Ramadan: A narrative review
Ochani, R. K., Shaikh, A. J., Batra, S., Pikale, G. S., & Surani, S. (2023) · World Journal of Clinical Cases · doi:10.12998/wjcc.v11.i26.6031 · Cited by 18
Kommu, S. (2023) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001511 · Cited by 21
Strategies for chronic coronary disease: A brief guide for clinicians
Krittanawong, C., Khawaja, M., Virk, H. U. H., Escobar, J., Khalid, U., Birnbaum, Y., Lavie, C. J., Sharma, S. K., Jneid, H. M., Rao, S. V., et al. (2024) · npj Cardiovascular Health · doi:10.1038/s44325-024-00006-w · Cited by 21
Sohn, M., Nam, S., Nauck, M. A., & Lim, S. K. (2024) · BMC Medicine · doi:10.1186/s12916-024-03483-z · Cited by 18
“In the large-scale RCTs with the medications used in our cohort, there was slightly greater weight loss with SGLT2i than GLP1RA (–2 kg for SGLT2i vs –1.5 kg for GLP1RA) (Additional file 1: Table S8) [9, 31–36].”
BackgroundInfluentialGregg, L. P., Richardson, P. A., Nambi, V., Petersen, L. A., Matheny, M. E., Virani, S. S., & Navaneethan, S. D. (2024) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000000000477 · Cited by 19
Spiazzi, B. F., Piccoli, G. F., Wayerbacher, L. F., Lubianca, J. P. N., Scalco, B. G., Scheffler, M. H., Fraga, B. L., Colpani, V., & Gerchman, F. (2024) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000000000568 · Cited by 19
Lin, Y., Wu, J., Lee, M.-C., Su, C.-Y., Toh, H. S., Chang, W., Chen, S.-Y., Kuo, F., Tang, H., & Liao, C. (2025) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvae093 · Cited by 20
“16 With the emergence of more recent studies, 17 , 18 these conflicting results underscore the need for a systematic review and meta-analysis to consolidate the evidence and clarify the overall treat-ment effects.”
Role of anti-diabetic medications in the management of MASLD
Isaacs, S. D., Farrelly, F. V., & Brennan, P. (2025) · Frontline Gastroenterology · doi:10.1136/flgastro-2024-102856 · Cited by 21
Sodium-glucose Co-transporter 2 Inhibitors: a New Path for Heart Failure Treatment
Oh, J., Lee, S., Lee, C. J., & Kang, S. (2021) · Korean Circulation Journal · doi:10.4070/kcj.2021.0070 · Cited by 19
New Antidiabetes Medications and Their Cardiovascular and Renal Benefits
Ferro, E. G., Elshazly, M. B., & Bhatt, D. L. (2021) · Cardiology Clinics · doi:10.1016/j.ccl.2021.04.007 · Cited by 19
Cardiovascular benefit of SGLT2 inhibitors
Mohebi, R., & Januzzi, J. L. (2021) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2021.1993439 · Cited by 17
“In the VERTIS CV trial [22], Cannon and colleagues enrolled 8,246 patients with T2D and atherosclerotic CV disease and assigned them to receive 5mg or 15mg of ertugliflozin or placebo.”
BackgroundMethodComparative Efficacy of Medical Treatments for Chronic Heart Failure: A Network Meta-Analysis
Xiang, B., Yu, Z., & Zhou, X. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.787810 · Cited by 19
Wang, T., Dong, Y., Yao, L., Lü, F., Wen, C., Wan, Z., Fan, L., Li, Z., Bu, T., Wei, M., et al. (2022) · Bioactive Materials · doi:10.1016/j.bioactmat.2022.02.002 · Cited by 27
Kwon, C. H., Kim, Y., Kim, M.-J., Cha, M., Cho, M. S., Nam, G., Choi, K., & Kim, J. (2022) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2022.05.017 · Cited by 17
He, Q., Chen, B., Wang, G., Zhou, D., Zeng, H., Li, X., Song, Y., Yu, X., Liang, W., Chen, H., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.842879 · Cited by 20
Diabetes Mellitus and Heart Failure
Siao, W.-Z., Chen, Y.-H., Tsai, C., Lee, C.-M., & Jong, G. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12101698 · Cited by 18
Mannucci, E., & Silverii, G. A. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15226 · Cited by 16
Corbin, K. D., Dagogo-Jack, S. E., Cannon, C. P., Cherney, D. Z. I., Cosentino, F., Frederich, R. C., Liu, J., Pong, A., Lin, J., Cater, N. B., et al. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14923 · Cited by 16
“001 for noninferiority).(13) Additionally, a 30% relative risk reduction was observed for the prespecified secondary outcome of HHF and a 34% relative risk reduction in the prespecified exploratory kidney composite outcome (40% sustained decline in estimated glomerular filtration rate [eGFR], dialysis/transplantation,…”
BackgroundMethodResultInfluentialSelf-citationNeumiller, J. J., Lienhard, F. J., Alicic, R. Z., & Tuttle, K. R. (2022) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2022.18.2.106 · Cited by 18
“The most common adverse events noted during the trial were consistent with cardiovascular outcome trials for other SGLT2 inhibitors and included genital mycotic and urinary tract infections.(15)”
BackgroundResultInfluentialNg, P. Y., Ng, A. K., Ip, A., Wu, M., Guo, R., & Yiu, K. (2023) · Critical Care Medicine · doi:10.1097/ccm.0000000000005869 · Cited by 17
d’Aiello, A., Bonanni, A., Vinci, R., Pedicino, D., Severino, A., Vita, A. D., Filomia, S., Brecciaroli, M., & Liuzzo, G. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24108643 · Cited by 19
“, New England Journal of Medicine, 2020 [49] 8246 CV death or hospitalization for HF 42 MACE occurred in 11.”
BackgroundCardiorenal interactions in heart failure: insights from recent therapeutic advances
Damman, K., & Testani, J. M. (2023) · Cardiovascular Research · doi:10.1093/cvr/cvad096 · Cited by 17
Dai, H., Zheng, L., Zhu, Z., Geng, X., Hou, T., Wang, Q., Zhu, Y., Lin, H., Wang, S., Zheng, R., et al. (2023) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4880 · Cited by 17
Karagiannis, T., Τσάπας, Α., Bekiari, E., Toulis, K. A., & Nauck, M. A. (2024) · Diabetes Care · doi:10.2337/dc23-0925 · Cited by 17
Shen, I., Stojanova, J., Yeo, M. G. H., Olsen, N., Lockart, I., Wang, M. M., Roggeveld, J., Heerspink, H. J. L., Greenfield, J. R., Day, R. O., et al. (2024) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.16139 · Cited by 17
“7,8 14 There is growing interest in the benefits of empagliflo-zin in cirrhosis due to these pivotal HF trials because overactivation of the renin-angiotensin-aldosterone system (RAAS) and fluid retention are key pathophysiological mechanisms in both cirrhosis and HF. 6 In single dose studies of…”
Zhang, A., Luo, X., Meng, H., Kang, J., Qin, G., Chen, Y., & Zhang, X. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.604250 · Cited by 16
“Recent clinical trials involving the SGLT-2i, such as empagliflozin (8), canagliflozin (9), dapagliflozin (10), and ertugliflozin (11) have surprisingly demonstrated a reduction in the risk of heart failure outcomes among patients with type 2 diabetes who have established cardiovascular disease (CVD) or are at high ca…”
BackgroundDashora, U. K., Gregory, R., Winocour, P. H., Dhatariya, K., Rowles, S. V., Macklin, A., Rayman, G. A., Nagi, D. K., Whitehead, K., Beba, H., et al. (2021) · Clinical Medicine · doi:10.7861/clinmed.2021-0045 · Cited by 19
Shenoy, S. V., Nagaraju, S. P., Bhojaraja, M. V., Prabhu, R., Rangaswamy, D., & Rao, I. R. (2021) · Nephrology · doi:10.1111/nep.13917 · Cited by 18
“outcomes, whether this is a consequence of heterogeneity between studies or indicates true intra-class differences is unclear and requires further studies specifically directed at evaluation of renal outcomes.(57,58) Notably, the SCORED trial was stopped early due to funding issues.”
ResultAn overview of alogliptin + pioglitazone for the treatment of type 2 diabetes
Tomlinson, B., Chan, P., & Lam, C. W. K. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1985465 · Cited by 19
“In the VERTIS CV cardiovascular outcome trial, ertugliflozin was noninferior to placebo with respect to major adverse cardiovascular events [29].”
MethodKim, C. H., Hwang, I.-C., Choi, H.-M., Ahn, C. H., Yoon, Y. E., & Cho, G.-Y. (2022) · International Journal of Cardiology · doi:10.1016/j.ijcard.2022.06.027 · Cited by 16
Patient preferences for newer oral therapies in type 2 diabetes
Savarese, G., Sharma, A., Pang, C., Wood, R., & Soleymanlou, N. (2022) · International Journal of Cardiology · doi:10.1016/j.ijcard.2022.09.009 · Cited by 19
Chen, H., Yang, Y., Yu, T.-H., & Li, Y. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.175354 · Cited by 18
Sodium-Glucose Cotransporter-2 Inhibition Benefits in Cardiorenal Risk in Men and Women
Pruett, J. E., Lirette, S. T., Romero, D. G., & Cardozo, L. L. Y. (2022) · Journal of the Endocrine Society · doi:10.1210/jendso/bvac191 · Cited by 18
“This difference in heterogeneity between men and women is likely due to the results of VERTIS-CV.”
BackgroundInfluentialClinical pharmacology of SGLT-2 inhibitors in heart failure
Velliou, M., Polyzogopoulou, E., Ventoulis, I., & Parissis, J. (2023) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2023.2173574 · Cited by 20
Yang, Y., Min, K. W., Park, S., Kim, K., Yu, J. M., Hong, E., Cho, S., Won, K. C., Kim, Y. H., Oh, S., et al. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15080 · Cited by 18
“Moreover, SGLT2 inhibitors have shown the effect of cardiorenal protection in several clinical trials.(9-19)”
BackgroundLin, D. S., Yu, A., Lo, H.-Y., Lien, C.-W., Lee, J., Chiang, F., & Tu, Y. (2023) · European Journal of Endocrinology · doi:10.1093/ejendo/lvad078 · Cited by 18
Bedros, J. R., Jermendy, G., Gaál, Z., Gerő, L., Hídvégi, T., Kempler, P., Lengyel, C., Várkonyi, T. T., Winkler, G., & Wittmann, I. (2023) · Diabetologia Hungarica · doi:10.24121/dh.2023.20 · Cited by 21
Meta-Analysis on the Safety and Cardiorenal Efficacy of SGLT2 Inhibitors in Patients Without T2DM
Li, L.-F., Ding, L., Zhan, Z., & Qiu, M. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.690529 · Cited by 18
Cardiovascular prevention in elderly patients.
Bonanad, C., Fernández-Olmo, R., García‐Blas, S., Alarcon, J. A., Díez‐Villanueva, P., Mansilla, C. R., García‐Pardo, H., Toledo, P., Ayesta, A., Pereira, E., et al. (2022) · PubMed Central · doi:10.11909/j.issn.1671-5411.2022.05.004 · Cited by 22
“Dapagliflozin([36]) 17,160 ≥ 75 years: 1,096 Combined HF hospitalisation/CV death All: 0.”
SGLT2 Inhibition in Heart Failure with Preserved Ejection Fraction — The New Frontier
Aguiar‐Neves, I., Santos‐Ferreira, D., & Fontes‐Carvalho, R. (2023) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2401001 · Cited by 16
Deshpande, R., Patel, R., Regmi, M. R., Salih, M., Kropp, R. J., Al-bast, B., Sheikh, M. A., Sagalov, A., Kulkarni, A., Siddique, M. S., et al. (2023) · Cardiovascular Endocrinology & Metabolism · doi:10.1097/xce.0000000000000284 · Cited by 16
“The trials CREDENCE, DECLARE TIMI 58, SCORED, and VERTIS-CV all found a statistically significant increase in risk for DKA [6,11,12,16], whereas, EMPA-REG OUTCOME, CANVAS, DAPA-HF, and DAPA-CKD found no difference in risk for DKA with SGLT2-Is or placebo [5,13,14,17].”
NHC/ SHA 2023 Focused update of the 2019 guidelines for the management of heart failure
Habeeb, W. A., Tash, A. A., Elasfar, A., Almasood, A. S., Bakhsh, A., Elshaer, F., Ayoubi, F. A., Alghalaini, K., Alqaseer, M., Alhussein, M., et al. (2023) · Journal of the Saudi Heart Association · doi:10.37616/2212-5043.1334 · Cited by 25
Ahmed, R., de Souza, R. J., Li, V., Banfield, L. E., & Anand, S. S. (2024) · Diabetologia · doi:10.1007/s00125-023-06052-w · Cited by 16
Effect of SGLT2 inhibitors on anemia and their possible clinical implications
Cases, A., Cigarrán, S., Górriz, J. L., & Núñez, J. E. (2024) · Nefrología (English Edition) · doi:10.1016/j.nefroe.2024.03.011 · Cited by 26
Geng, L., Sun, B., & Chen, Y. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15901 · Cited by 17
Lingvay, I., Greenberg, M., Gallo, S., Shi, H. H., Liu, J., & Gantz, I. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14385 · Cited by 17
“Assessments of cardiorenal endpoints, which require longer duration of follow-up, were not objectives of the substudy and were previously reported.(13)”
BackgroundSelf-citationHinton, W., Feher, M. D., Munro, N. M., Joy, M., & de Lusignan, S. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01316-4 · Cited by 17
Sodium-Glucose Cotransporter-2 Inhibitors in Vascular Biology: Cellular and Molecular Mechanisms
Xiao, L., Nie, X., Cheng, Y., & Wang, N. (2021) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-021-07216-9 · Cited by 16
“Although the cardiovascular benefits are relatively consistent among many outcome trials with different gliflozins, they were not observed in the VERTIS-CV trial, a multicenter, double-blinded study to assess MACE in T2DM with atherosclerosis using ertugliflozin [12].”
MethodResultSridhar, V. S., Ambinathan, J. P. N., Gillard, P., Mathieu, C., Cherney, D. Z. I., Lytvyn, Y., & Singh, S. K. (2021) · Transplantation · doi:10.1097/tp.0000000000003919 · Cited by 15
“↓ HbA1c ↓ Albuminuria ↓ Glomerulosclerosis Weight neutral Safely tolerated ↓ HbA1c Used across a wide eGFR range Only data from small short-term studies available No evidence of renal protection AKI, acute kidney injury; CNI, calcineurin inhibitor; DPP-4, dipeptidyl peptidase-4 inhibitor; eGFR, estimated GFR; GFR, glo…”
MethodSelf-citationSeetharaman, R., Pawar, S. R., & Advani, M. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15100 · Cited by 17
SGLT2 Inhibitors: Benefits for CKD and Cardiovascular Disease in Type 2 Diabetes
Singhal, R., & Hechanova, L. A. (2022) · Current Cardiology Reports · doi:10.1007/s11886-022-01637-0 · Cited by 16
Efficacy and Safety of Dapagliflozin in Patients With CKD Across Major Geographic Regions
Vart, P., Correa‐Rotter, R., Hou, F. F., Jongs, N., Chertow, G. M., Langkilde, A. M., McMurray, J. J. V., Rossing, P. R., Sjöström, C. D., Stefánsson, B. V., et al. (2022) · Kidney International Reports · doi:10.1016/j.ekir.2022.01.1060 · Cited by 17
“Similarly, canagliflozin and ertugliflozin in patients with type 2 diabetes and increased risk of cardiovascular disease showed no regional heterogeneity in efficacy for a composite end point of cardiovascular death, myocardial infarction, or ischemic stroke.(14,15) Regional differences in the efficacy of sodiumglucos…”
BackgroundDefining the Role of SGLT2 Inhibitors in Primary Care: Time to Think Differently
Evans, M., Morgan, A. R., Bain, S. C., Davies, S., Dashora, U. K., Sinha, S., Seidu, S., Patel, D., Beba, H., & Strain, W. D. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01242-y · Cited by 18
“Several clinical trials have assessed the impact of SGLT2is on CV outcomes: EMPA-REG OUTCOMES [52], CANVAS [53], VERTIS CV [54], and DECLARE TIMI 58 [55].”
BackgroundMethodInfluentialGrowing role of SGLT2i in heart failure: evidence from clinical trials
Varadhan, A. K., Stephan, K., Gupta, R., Vyas, A. V., Ranchal, P., Aronow, W. S., Hawwa, N., & Lanier, G. M. (2022) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2022.2051480 · Cited by 15
“were randomized to placebo, Ertugliflozin 5 mg or 15 mg [66].”
MethodReport from the CVOT Summit 2021: new cardiovascular, renal, and glycemic outcomes
Schnell, O., Battelino, T., Bergenstal, R. M., Blüher, M., Böhm, M., Brosius, F. C., Carr, R. D., Ceriello, A., Forst, T. M., Giorgino, F., et al. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01481-0 · Cited by 17
Succurro, E., Vizza, P., Papa, A., Miceli, S., Cicone, F., Fiorentino, T. V., Sciacqua, A., Andreozzi, F., Veltri, P., Cascini, G. L., et al. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14816 · Cited by 16
Is there any robust evidence showing that SGLT2 inhibitor use predisposes to acute kidney injury?
Çöpür, S., Yıldız, A. B., Basile, C., Tuttle, K. R., & Kanbay, M. (2022) · Journal of Nephrology · doi:10.1007/s40620-022-01422-w · Cited by 18
“[18] Multicenter double-blind randomized placebo-controlled event-driven noninferiority trial (SGLT2is vs.”
BackgroundSodium Glucose Cotransporter 2 Inhibitors, Amputation Risk, and Fracture Risk
Arnott, C. G., Fletcher, R. A., & Neal, B. C. (2022) · Heart Failure Clinics · doi:10.1016/j.hfc.2022.03.008 · Cited by 15
Hinton, W., Ansari, A. S., Whyte, M., McGovern, A. P., Feher, M. D., Munro, N. M., & de Lusignan, S. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14893 · Cited by 16
Tornyos, D., Meuer, M., Lukács, R., Abdallaoui, O. E. A. E., Kupó, P., Faludi, R., & Komócsi, A. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.1041200 · Cited by 15
“000 patients were included in the VERTIS-CV trial with ertugliflozin the estimates are more reliable (31).”
MethodLi, X., Wu, H., Peng, H., & Jiang, H. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1078686 · Cited by 16
The current role of SGLT2 inhibitors in type 2 diabetes and beyond: a narrative review
Scheen, A. J. (2023) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2023.2210673 · Cited by 17
“In a later meta-analysis that included the four CVOTs (also including VERTIS-CV, plus CREDENCE) [40], SGLT2is were associated with a reduced risk of MACEs (HR 0.90, 0.85 to 0.95), hHF/CV death (HR, 0.78, 0.73 to 0.84), with no significant heterogeneity.”
MethodInfluentialSohn, M., Frías, J. P., & Lim, S. K. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15251 · Cited by 17
Metformin: still the sweet spot for CV protection in diabetes?
Rena, G., Mordi, I. R., & Lang, C. C. (2020) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2020.10.018 · Cited by 16
Sorice, G. P., Cinti, F., Leccisotti, L., D’Amario, D., Lorusso, M., Guzzardi, M. A., Mezza, T., Cocchi, C., Capece, U., Ferraro, P. M., et al. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01083-1 · Cited by 16
Cardiovascular Safety and Superiority of Anti-Obesity Medications
Alobaida, M., Alrumayh, A., Oguntade, A. S., Al-Amodi, F., & Bwalya, M. (2021) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s311359 · Cited by 15
Bilal, A., Yi, F., Gonzalez, G. R., Ali, M., Im, K., Ruff, C. T., Thethi, T. K., & Pratley, R. E. (2024) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2024.108783 · Cited by 14
Self-citationCardiovascular events in individuals treated with sulfonylureas or dipeptidyl peptidase 4 inhibitors
Turchin, A., Petito, L. C., Hegermiller, E., Carnahan, R., DeVries, A., Goel, S., Lansang, M. C., McDonnell, M. E., Nair, V., Priest, E., et al. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.23067 · Cited by 14
Obesity and heart failure: exploring the cardiometabolic axis
Rayner, J. J., Abdesselam, I., Pan, J., Lewis, A., & Rider, O. J. (2025) · Cardiovascular Research · doi:10.1093/cvr/cvaf090 · Cited by 17
Kidney Outcomes With Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes
Mosenzon, O., Schechter, M., & Leibowitz, G. (2021) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2021.04.005 · Cited by 16
SABOURET, P., BOCCHINO, P. P., ANGELINI, F., D’ASCENZO, F., GALATI, G., FYSEKIDIS, M., DE FERRARI, G. M., FISCHMAN, D. L., BHATT, D. L., & BIONDI-ZOCCAI, G. (2023) · Minerva Cardiology and Angiology · doi:10.23736/s2724-5683.22.05900-2 · Cited by 14
Sönmez, A., Sabbour, H. M., Echtay, A. S., Rahmah, A. M., Alhozali, A. M., Sabaan, F. S. A., Haddad, F., Iraqi, H., Elebrashy, I., Assaad, S. N., et al. (2022) · Journal of Diabetes · doi:10.1111/1753-0407.13266 · Cited by 16
“Table S2.(65-69,82,85-109) The Dapagliflozin Effect on Cardiovascular Events-Thrombolysis in Myocardial Infarction 58 (DECLARE-TIMI 58) study has supported the expansion of SGLT2is for primary prevention of HF outcomes and reduction in atrial fibrillation.”
BackgroundLiu, H., Sridhar, V. S., Perkins, B. A., Rosenstock, J., & Cherney, D. Z. I. (2022) · Current Diabetes Reports · doi:10.1007/s11892-022-01471-2 · Cited by 14
Self-citationBechmann, L. E., Emanuelsson, F., Nordestgaard, B. G., & Benn, M. (2023) · Cardiovascular Research · doi:10.1093/cvr/cvad122 · Cited by 14
Tilinca, M. C. (2023) · FARMACIA · doi:10.31925/farmacia.2023.4.4 · Cited by 22
Jang, J.-H., Park, S.-Y., Kim, S., Kim, S., Oh, Y., Sa, Y. K., Hwang, Y. M., Jang, S.-W., Ihm, S., & Choi, Y. (2023) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwad322 · Cited by 14
Rastogi, A., Sudhayakumar, A., Schaper, N. C., & Jude, E. B. (2023) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2023.102875 · Cited by 16
Rhee, J. J., Han, J., Montez‐Rath, M. E., & Chertow, G. M. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15427 · Cited by 17
“6 When considering placebo-controlled randomized trials or comparative effectiveness studies in T2DM, background therapies could also influence cardiovascular risk.”
BackgroundSodium glucose cotransporter-2 inhibitors and heart disease: Current perspectives
Mondal, S., Pramanik, S., Khare, V. R., Fernandez, C. J., & Pappachan, J. M. (2024) · World Journal of Cardiology · doi:10.4330/wjc.v16.i5.240 · Cited by 17
FITCHETT, D. H., Zinman, B., Inzucchi, S. E., Wanner, C., Anker, S. D., Pocock, S., Mattheus, M., Vedin, O., & Lund, S. S. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02328-6 · Cited by 14
Lin, M., Zhang, S., Zhang, L., Yang, C., Yang, L., Peng, Y., Tan, X., Wen, Q., Fan, X., & Ou, X. (2025) · Systematic Reviews · doi:10.1186/s13643-025-02766-7 · Cited by 16
Ferrannini, G., Savarese, G., & Rydén, L. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108796 · Cited by 14
Zhao, L., Zhang, M., Zhan, Z., & Qiu, M. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.679124 · Cited by 14
“The four trials of VERTIS CV (3), CANVAS Program (4), DECLARETIMI58 (5), and EMPA-REG OUTCOME (6) provided the data of the subgroup of patients”
MethodSayour, A. A., Ruppert, M., Oláh, A., Benke, K., Barta, B. A., Zsáry, E., Ke, H., Horvath, E. M., Merkely, B. P., & Radovits, T. (2021) · Antioxidants · doi:10.3390/antiox10081190 · Cited by 14
Teo, Y. N., Teo, Y. H., Syn, N. L. X., Yoong, C. S. Y., Cheong, A. J. Y., Wee, C. F., Lim, Y. C., Lee, C., Yeo, T., Chai, P., et al. (2021) · Clinical Drug Investigation · doi:10.1007/s40261-021-01098-3 · Cited by 14
“In the past two years, with clear clinical benefits of SGLT2 inhibitors in patients with heart failure independent of diabetic status demonstrated in multiple clinical trials [16, 18, 34, 37, 50], the inclusion of SGLT2 inhibitors into clinical practice is imminent.”
BackgroundEvans, M., Morgan, A. R., Whyte, M., Hanif, W., Bain, S. C., Kalra, P. A., Davies, S., Dashora, U. K., Yousef, Z. R., Patel, D., et al. (2021) · Drugs · doi:10.1007/s40265-021-01655-2 · Cited by 17
SGLT2 Inhibitors and Peripheral Vascular Events
Marchiori, E., Rodionov, R. N., Peters, F., Magnussen, C., Nordanstig, J., Gombert, A., Spanos, K. T., Jarzebska, N., & Behrendt, C. (2022) · Heart Failure Clinics · doi:10.1016/j.hfc.2022.03.001 · Cited by 16
SGLT2 Inhibitors in Type 2 Diabetes Mellitus
Ferrannini, G., Savarese, G., & Cosentino, F. (2022) · Heart Failure Clinics · doi:10.1016/j.hfc.2022.03.009 · Cited by 13
Self-citationMorita, R., Tsukamoto, S., Obata, S., Yamada, T., Uneda, K., Uehara, T., Rehman, M. E., Azushima, K., Wakui, H., & Tamura, K. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14976 · Cited by 16
Combination Diuretic Therapy to Counter Renal Sodium Avidity in Acute Heart Failure
Kazory, A. (2023) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000000000188 · Cited by 16
Marzo, V. D., Savarese, G., Porto, I., Metra, M., & Ameri, P. (2023) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000001504 · Cited by 16
Cases, A., Cigarrán, S., Górriz, J. L., & Núñez, J. E. (2023) · Nefrología · doi:10.1016/j.nefro.2023.11.001 · Cited by 17
Metadata
- Authors
- Cannon, C. P., Pratley, R., Dagogo-Jack, S., Mancuso, J., Huyck, S., Masiukiewicz, U., Charbonnel, B., Frederich, R., Gallo, S., Cosentino, F., Shih, W. J., Gantz, I., Terra, S. G., Cherney, D. Z. I., & McGuire, D. K.
- Affiliations
- Rutgers, The State University of New Jersey (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-10-08
- Volume
- 383
- Issue
- 15
- Pages
- 1425-1435
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3089283105
- Cited by
- 1,514
- References
- 14
- Citations by year
- 2026: 126 · 2025: 177 · 2024: 231 · 2023: 269 · 2022: 298 · 2021: 364 · 2020: 47
- FWCI
- 184.60
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Funders
- Pfizer
- Merck
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- ertugliflozin, SGLT2 inhibitors, type 2 diabetes, atherosclerotic cardiovascular disease, major adverse cardiovascular events, heart failure hospitalization, cardiovascular mortality, non-inferiority, renal safety, non-inferiority margin, myocardial infarction, stroke, renal replacement therapy, serum creatinine doubling, cardiovascular risk stratification
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Aged, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Double-Blind Method, Female, Hospitalization, Humans, Male, Middle Aged, Placebos, Bridged Bicyclo Compounds, Heterocyclic, Atherosclerosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.